Abstract
Background
This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy.
Patients and methods
Postmenopausal women with estrogen-receptor-positive advanced breast cancer that had progressed after tamoxifen were given 2.5 mg letrozole once daily and were randomly assigned (2:1) to tipifarnib 300 mg (TL) or placebo (L) twice daily for 21 consecutive days in 28-day cycles. The primary endpoint was objective response rate.
Results
Of 120 patients treated with TL (n = 80) or L (n = 40), 113 were evaluable for response. Objective response rate was 30% (95% CI; 20–41%) for TL and 38% (95% CI; 23–55%) for L. There was no significant difference in response duration, time to disease progression or survival. Clinical benefit rates were 49% (TL) and 62% (L). Tipifarnib was generally well tolerated; a higher incidence of drug-related asymptomatic grade 3/4 neutropenia was observed for TL (18%) than for L (0%). Tipifarnib population pharmacokinetics were similar to previous studies, with no significant difference in trough letrozole concentrations between the TL and L groups.
Conclusions
Adding tipifarnib to letrozole did not improve objective response rate in this population of patients with advanced breast cancer.
Similar content being viewed by others
Abbreviations
- AE:
-
Adverse event
- CBR:
-
Clinical benefit rates
- CI:
-
Confidence interval
- CR:
-
Complete response
- ECOG:
-
Eastern Cooperative Oncology Group
- ER:
-
Estrogen receptor
- FTI:
-
Farnesyltransferase inhibitor
- L:
-
Letrozole
- NCI:
-
National Cancer Institute
- ORR:
-
Objective response rate
- PR:
-
Partial response
- PgR:
-
Progesterone-receptor
- RECIST:
-
Response Evaluation Criteria in Solid Tumors
- T:
-
Tipifarnib
- mTOR:
-
Mammalian target of Rapamycin
- TTF:
-
Time to disease free survival
- TTP:
-
Time to disease progression
References
Clark GJ, Der CJ (1995) Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35:133–144
Clark GJ, Kinch MS, Gilmer TM et al (1996) Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 12:169–176
Norgaard P, Law B, Joseph H et al (1999) Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 5:35–42
End DW, Smets G, Todd AV et al (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131–137
Kelland LR, Smith V, Valenti M et al (2001) Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7:3544–3550
Johnston SR, Hickish T, Ellis P et al (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21:2492–2499
Nicholson RI, McClelland RA, Robertson JF, Gee JM (1999) Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373–387
Simoncini T, Hafezi-Moghadam A, Brazil DP et al (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538–541
Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17:309–317
Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926–935
Johnston SR (2005) Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 11:889s–899s
Gee JM, Harper ME, Hutcheson IR et al (2003) The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105–5117
Martin LA, Head J, Pancholi S et al (2007) The farnesyl transferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in-vitro and in-vivo. Mol Cancer Ther (in press)
Ellis CA, Vos MD, Wickline M et al (2003) Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 78:59–67
Doisneau-Sixou SF, Cestac P, Faye JC et al (2003) Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 106:789–798
Long BJ, Liu G, Marrinan CH et al (2004) Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts. Proc Am Assoc Cancer Res 45:A3868
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Crul M, de Klerk GJ, Swart M et al (2002) Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726–2735
Perez-Ruixo JJ, Piotrovskij V, Zhang S et al (2006) Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 62:81–96
Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453–461
Prendergast GC, Davide JP, deSolms SJ et al (1994) Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193–4202
Miquel K, Pradines A, Sun J et al (1997) GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57:1846–1850
Sepp-Lorenzino L, Rosen N (1998) A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 273:20243–20251
Du W, Liu A, Prendergast GC (1999) Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208–4212
Gutierrez MC, Detre S, Johnston S et al (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469–2476
Lipton A, Leitzel K, Ali SM et al (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104:257–263
Chan S, Scheulen ME, Johnston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314–5322
Boulay A, Rudloff J, Ye J et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319–5328
deGraffenried LA, Friedrichs WE, Russell DH et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059–8067
Baslega J, Roche H, Fumoleau P et al (2005) Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combinations with temsirolimus; a randomized 3-arm, phase 2 study. 28th annual San Antonio breast cancer symposium 94S:Abstract no. 1068
Kaufman B (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). European Society for Medical Oncology (ESMO) Congress 2006:Abstract no. LBA2
Moulder SL, Sparano JA, Kazi A et al (2005) The farnesyltransferase inhibitor (FTI) tipifarnib inhibits FPTase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer 28th annual San Antonio breast cancer symposium 94S:Abstract no. 5061
Acknowledgements
We would like to thank the patients who took part in this study. This study R115777-INT-22, was sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and was registered with ClinicalTrials.gov (NCT00050141). We would also like to thank Namit Ghildyal, Ph.D. for his writing contributions.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
In addition to the authors, the following investigators (listed in alphabetical order) participated in the R115777-INT-22 study: Belgium—M. Berlière (Brussels); France—M. Campone (St. Herblain), P. Chollet (Clermont-Ferrand), P. Kerbrat (Rennes), L. Mauriac (Bordeaux); The Netherlands—H. P. Sleeboom (Den Haag); Russia—M. Y. Biakhov (Moscow), D. B. Korman (Moscow), A. N. Makhson (Moscow), S. A. Tjulandin (Moscow); United Kingdom—P. A. Ellis (London), J. K. Joffe (Huddersfield), M. W. Verrill (Newcastle-upon-Tyne); United States—M. J. Ellis (St. Louis, MO), P. Khosla (Chicago, IL), P.K. Marcom (Durham, NC), R. L. Ruxer (Fort Worth, TX), P. Silverman (Cleveland, OH), S Vukelja (Tyler, TX).
Author contributions
Conception and design: Stephen Johnston, Youn Park, Peter De Porre, Juan Jose Perez Ruixo, Angela Howes.
Administrative support: Annick. Bessems, Angela Howes.
Provision of study materials or patients: Stephen Johnston, Vladimir Semiglazov, George Manikhas, Dominique Spaeth, Gilles. Romieu, David Dodwell, Andrew Wardley, Patrick Neven.
Collection and assembly of data: Annick. Bessems, Youn Park, Juan Jose Perez Ruixo, Angela Howes.
Data analysis and interpretation: Stephen Johnston, Youn Park, Peter De Porre, Juan Jose Perez Ruixo, Angela Howes.
Manuscript writing: Stephen Johnston, Youn Park, Peter De Porre, Angela Howes.
Final approval of manuscript: Stephen Johnston, Vladimir Semiglazov, George Manikhas, Dominique Spaeth, Gilles. Romieu, David Dodwell, Andrew Wardley, Patrick Neven.
Rights and permissions
About this article
Cite this article
Johnston, S.R.D., Semiglazov, V.F., Manikhas, G.M. et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 110, 327–335 (2008). https://doi.org/10.1007/s10549-007-9726-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9726-1